G

GSK

Develops medicines, vaccines, and consumer health

Principal Engineer - Platform Engineer, Network Capabilities

Full-TimeUpdated Deadline 11/10/26
No salary listed
Expert
Bachelor's
Bengaluru, Karnataka, India
HybridHybrid work: remote and on-site in Bengaluru.
IT OperationsNetwork Engineering & Administration

About the job

Requirements
  • A degree in a technology or engineering discipline, or equivalent practical experience, such as Computer Science, Software Engineering, or Electronics.
  • Deep hands-on experience in the relevant platform domain, whether cloud and hosting, network, or digital workplace.
  • Practical experience applying infrastructure-as-code, such as Terraform, to production estates rather than proofs of concept.
  • Experience with CI/CD pipelines, and with containers and Kubernetes where relevant to the platform.
  • A track record of building self-service capability adopted by other teams without hand-holding.
  • Experience instrumenting for observability, defining SLOs, and reducing toil through automation.
  • Experience with AI-assisted engineering tooling, including judging when generated output is not fit to merge.
  • Extensive experience engineering shared network services such as Domain Name System, Dynamic Host Configuration Protocol, and Internet Protocol address management.
  • Strong knowledge of network access control, application programming interfaces, automation, monitoring, and resilient service design.
  • Evidence of improving service reliability, self-service, deployment speed, or operational efficiency.
  • Automation-first approach to repeated manual tasks.
  • Code review discipline that maintains quality without creating a bottleneck.
  • Ability to mentor engineers of varying experience, including partner engineers outside the reporting line.
  • Judgement about when AI-generated code is fit to merge.
  • Customer mindset toward teams consuming the platform.
  • Willingness to make technical debt and its cost visible.
  • Overall 15 years of experience and typically 6–8 years in platform, infrastructure, or software engineering, including at least two years as the senior technical voice in a team.
Responsibilities
  • Design, build, and automate platform infrastructure using infrastructure-as-code and golden paths so that provisioning is repeatable.
  • Use AI-assisted engineering across code generation, review, and testing to accelerate delivery and raise quality, reviewing AI-generated output before it is merged.
  • Build self-service capabilities and paved roads that reduce friction for consuming teams so adoption does not depend on the platform team's availability.
  • Engineer for reliability by defining SLOs, instrumenting platforms for observability, and automating to reduce toil, working with the Site Reliability Engineer on standards.
  • Set and uphold engineering standards, secure-by-default practices, and code quality within the platform, and hold them in code review.
  • Contribute to incident response and drive permanent automated fixes with Reliability Engineering rather than repeating manual recovery.
  • Mentor and technically lead other engineers, including partner engineers, linking engineering work to platform OKRs and outcomes.
  • Integrate and assure supplier or managed-service components, holding partner-delivered engineering to the same standards and code quality as internal work.
  • Work the platform's manual task and toil backlog, converting identified candidates into automation and evidencing the effort removed.
  • Close observability coverage gaps for the platform so reliability can be measured rather than inferred.
  • Contribute engineering-led items to the platform backlog held by the Product Owner, including technical debt, upgrade, and automation work, with the cost of not doing them stated.
  • Apply the reference architectures and patterns set by the Platform Architect, and raise a case for change rather than diverging locally.
Desired Qualifications
  • Relevant technical certifications, such as a recognised cloud certification for AWS, GCP, or Azure; Certified Kubernetes Administrator; or a network vendor certification relevant to the platform.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.